- Home
- ALT vs CYRX Comparison
ALT vs CYRX Comparison
Compare ALT & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALT | CYRX |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.3M | 421.6M |
| IPO Year | 2005 | 2008 |
Fundamental Metrics
Financial Performance| Metric | ALT | CYRX |
|---|---|---|
| Price | $3.61 | $7.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $15.50 | $12.94 |
| AVG Volume (30 Days) | ★ 2.8M | 367.2K |
| Earning Date | 01-01-0001 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.37 | ★ 156.22 |
| EPS | N/A | ★ 1.40 |
| Revenue | $41,000.00 | ★ $176,177,000.00 |
| Revenue This Year | N/A | $9.71 |
| Revenue Next Year | $756,308.50 | $9.56 |
| P/E Ratio | ★ N/A | $5.72 |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.91 | $4.63 |
| 52 Week High | $7.73 | $11.45 |
Technical Indicators
Market Signals| Indicator | ALT | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.82 | 34.81 |
| Support Level | $3.39 | $6.57 |
| Resistance Level | $4.25 | $7.88 |
| Average True Range (ATR) | 0.24 | 0.45 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 13.75 | 8.57 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.